Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  ISIS Pharmaceuticals, Inc.    ISIS

 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2016 277 M
EBIT 2016 -92,5 M
Net income 2016 -107 M
Debt 2016 47,8 M
Yield 2016 -
Sales 2017 318 M
EBIT 2017 -99,9 M
Net income 2017 -138 M
Debt 2017 77,8 M
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales2016 13,7x
EV / Sales2017 12,0x
Capitalization 3 736 M
More Financials
Company
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of antisense drug discovery.It operates through two segments: Drug Discovery & Development Operations and Akcea.The Drug Discovery & Development Operations segment provides drugs to treat a variety of health conditions,... 
More about the company
Surperformance© ratings of ISIS Pharmaceuticals, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on ISIS PHARMACEUTICALS, INC.
08/22 ISIS PHARMACEUTICALS : Ionis Pharmaceuticals' CEO, Dr. Stanley Crooke, Receives ..
08/18 IONIS PHARMACEUTICALS : Reports Financial Results and Highlights for Second Quar..
08/09 IONIS PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDIT..
08/09 IONIS PHARMACEUTICALS : reports 2Q loss
08/09 IONIS PHARMACEUTICALS INC : Results of Operations and Financial Condition, Finan..
08/09 IONIS PHARMACEUTICALS : Reports Financial Results and Highlights for Second Quar..
08/03 IONIS PHARMACEUTICALS INC : Other Events (form 8-K)
08/01 IONIS PHARMACEUTICALS : Leading The Biotechnology Sector Higher
08/01 IONIS PHARMACEUTICALS : Positive results halt Biogen, Ionis trial of SMA drug
08/01DJBIOGEN : Ionis Spinal Muscular Atrophy Therapy Meets Study Goal
More news
Sector news : Biotechnology & Medical Research - NEC
09:29aDJSANOFI : Regeneron Announce Positive Trials for Cholesterol Drug
08/24DJAMGEN : FDA Rejects Amgen Hormonal-Imbalance Treatment
08/24DJAMGEN : FDA Rejects Amgen Hormonal-Imbalance Treatment
08/23DJPFIZER : to Acquire Key Drug -- WSJ
08/23DJDeal for Medivation Is the Latest In a Line of Similar Acquisitions -- WSJ
More sector news : Biotechnology & Medical Research - NEC
4-Traders Strategies on ISIS PHARMACEUTICALS, INC. 
2014A resistance as obstacle
More Strategies
News from SeekingAlpha
2015 Game Plan For The Week - Cramer's Mad Money (12/18/15)
2015 PREMARKET BIOTECH DIGEST : Portola's Milestone, Shkreli Resigns, BioMarin DMD Dr..
2015 Isis Pharma has had enough, name changed to Ionis Pharmaceuticals
2015 Bear Afoot? No Recession Needed For A Possible Sighting
2015 PREMARKET BIOTECH DIGEST : Gilead's Upside, Shire-Baxalta Deal, ARIAD Lowers Gui..
Advertisement
Chart ISIS PHARMACEUTICALS, INC.
Duration : Period :
ISIS Pharmaceuticals, Inc. Technical Analysis Chart | ISIS | US4643301090 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus HOLD
Number of Analysts 13
Average target price 40,2 $
Spread / Average Target 30%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Stanley T. Crooke Chairman, President & Chief Executive Officer
B. Lynne Parshall Chief Operating Officer & Director
Elizabeth L. Hougen Chief Financial Officer & SVP-Finance
C. Frank Bennett Senior Vice President-Antisense Research
Joseph H. Wender Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ISIS PHARMACEUTICALS, ..-6.12%3 736
INCYTE CORPORATION-25.27%15 236
CELLTRION, INC.--.--%11 367
LONZA GROUP AG14.78%10 130
QUINTILES TRANSNATIONA..10.24%8 968
ALKERMES PLC-43.94%6 744
More Results